))
Is Artemisinin Drug Resistance in Africa on the Rise?
Manage episode 386124463 series 3531530
Contenuto fornito da Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Researchers examine the rise of artemisinin drug resistance in Eritrea - and search for its genetic basis.
Transcript
Artemisinin – a key antimalarial drug – and other drugs derived from it, are fast losing their effectiveness across South East Asia and increasingly in Africa, too. To investigate this, researchers conducted a review of drug efficacy studies in the East African country of Eritrea. They looked for the rates of delayed parasite clearance in the three days following treatment – a key marker of partial drug resistance. They found a troubling pattern: delayed parasite clearance climbed from 0.4% in 2016 to 1.9% in 2017, followed by a marked increase to 4.2% in 2019. By isolating and sequencing parasitic DNA, they found that this trend was associated with the rise of a novel mutation to the Kelch13 region of the parasite, called R622I. Given the lack of alternative drugs, the emergence of resistance in Africa is concerning.
Source
Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea
About The Podcast
The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.
74 episodi
Condividi
